Acquired amegakaryocytic thrombocytopenia

What causes acquired amegakaryocytic thrombocytopenia?

There are many potential causes of acquired amegakaryocytic thrombocytopenia. For example, the condition can be associated with:

In some people, the condition is an early sign of a more severe progressive disease, such as aplastic anemia, myelodysplasia, or leukemia.

Last updated on 05-01-20

How is acquired amegakaryocytic thrombocytopenia diagnosed?

A diagnosis of acquired amegakaryocytic thrombocytopenia is often suspected based on the presence of characteristic signs and symptoms. Additional testing can then be ordered to confirm the diagnosis. This may include:

Once the diagnosis is confirmed, a healthcare provider will likely recommend other tests in an attempt to determine the underlying cause of the condition.

Last updated on 05-01-20

What is acquired amegakaryocytic thrombocytopenia?

Acquired amegakaryocytic thrombocytopenia is a rare blood disorder that causes severe thrombocytopenia with no other blood abnormalities. It is so named because the level of large bone marrow cells that produce platelets, called megakaryocytes, are significantly lower or absent. Signs and symptoms of the condition include prolonged bleeding; easy bruising; rash (pinpoint red spots called petechia); bleeding in the mouth and gums; and/or frequent nosebleeds. There are many potential causes of the condition. Although standard treatment guidelines have not been established, various immunosuppressive treatment approaches have been utilized with success in affected people.

Last updated on 05-01-20

What is the long-term outlook for people with acquired amegakaryocytic thrombocytopenia?

The long-term outlook (prognosis) for people with acquired amegakaryocytic thrombocytopenia varies based on the underlying cause. Some people respond well to treatment and long-term remissions have been documented in several case reports. In others, the condition progresses rapidly to aplastic anemia or myelodysplasia. There are currently no good predictors to aid in assessing the likelihood of response to therapy or overall prognosis.

Last updated on 05-01-20

How might acquired amegakaryocytic thrombocytopenia be treated?

Standard treatment guidelines have not been established for acquired amegakaryocytic thrombocytopenia. However, various immunosuppressive treatment approaches have been utilized in affected people. In several case reports, affected people were successfully treated with cyclosporine either alone or in combination with other immunosuppressive medications (i.e. antithymocyte globulin). Other therapies for acquired amegakaryocytic thrombocytopenia have included rituximab, danazol, azathioprine, and bone marrow transplant with variable success.

To determine the best treatment for you or a family member, please speak with a healthcare provider.

Last updated on 05-01-20

Where To Start

NHLBI - Thrombocytopenia

The National Heart Lung and Blood Institute (NHLBI) provides information on thrombocytopenia in general. The NHLBI was created to conduct research and distribute health information on diseases of the heart, blood vessels, lungs, and blood.

Last updated on 04-27-20

Name: Platelet Disorder Support Association 8751 Brecksville Road Suite 150
Cleveland, OH, 44141, United States
Phone: 440-746-9003 Toll Free: 87-PLATELET (1-877-528-3538) Fax : 844-270-1277 Email: Url:

Connect with other users with Acquired amegakaryocytic thrombocytopenia on the RareGuru app

Do you have information about a disease, disorder, or syndrome? Want to suggest a symptom?
Please send suggestions to RareGuru!

The RareGuru disease database is regularly updated using data generously provided by GARD, the United States Genetic and Rare Disease Information Center.

People Using the App

Join the RareGuru Community

To connect, share, empower and heal today.

People Using the App